BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37717659)

  • 1. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients.
    Miao G; He Y; Lai K; Zhao Y; He P; Tan G; Wang X
    J Control Release; 2023 Nov; 363():12-26. PubMed ID: 37717659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
    Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
    Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
    Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
    Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
    Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
    J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
    El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
    Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.
    Chen WA; Chang DY; Chen BM; Lin YC; Barenholz Y; Roffler SR
    ACS Nano; 2023 Mar; 17(6):5757-5772. PubMed ID: 36926834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
    Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
    J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
    Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
    J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
    Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
    El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
    J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
    Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
    J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
    Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
    Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum.
    Neun BW; Dobrovolskaia MA
    Methods Mol Biol; 2024; 2789():185-192. PubMed ID: 38507004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
    Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
    Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
    Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
    J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
    McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
    J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
    Wang X; Ishida T; Kiwada H
    J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Poly(ethylene glycol) Nanoparticles for Accelerated Blood Clearance Inhibition and Targeted Drug Delivery.
    Tian Y; Gao Z; Wang N; Hu M; Ju Y; Li Q; Caruso F; Hao J; Cui J
    J Am Chem Soc; 2022 Oct; 144(40):18419-18428. PubMed ID: 36166420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.